Published in N Engl J Med on October 09, 1980
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
Analysis of processing and polyadenylation signals of the hepatitis B virus surface antigen gene by using simian virus 40-hepatitis B virus chimeric plasmids. Mol Cell Biol (1983) 3.63
Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health (1999) 3.55
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev (1999) 2.55
Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A (1982) 2.52
Failure to deliver hepatitis B vaccine: confessions from a genitourinary medicine clinic. BMJ (1991) 2.49
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J (Clin Res Ed) (1983) 1.86
Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) (1983) 1.85
Plasmid-directed synthesis of hepatitis B surface antigen in monkey cells. Mol Cell Biol (1983) 1.85
The gay report on sexually transmitted diseases. Am J Public Health (1981) 1.85
Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant. Proc Natl Acad Sci U S A (1982) 1.81
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
Preventing and treating hepatitis B infection. BMJ (2004) 1.80
A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A (1986) 1.74
Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci U S A (2001) 1.67
Mutational analysis of hepatitis B surface antigen particle assembly and secretion. J Virol (1991) 1.56
Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J (1984) 1.54
Uptake of immunisation against hepatitis B among surgeons in Wessex Regional Health Authority. BMJ (1990) 1.51
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine (2010) 1.38
Stability in controlling viral replication identifies long-term nonprogressors as a distinct subgroup among human immunodeficiency virus type 1-infected persons. J Virol (1996) 1.37
Enhancement of the immune response to hepatitis B surface antigen. In vivo administration of antiidiotype induces anti-HBs that expresses a similar idiotype. J Exp Med (1984) 1.35
Correlates of incident infections for HIV, syphilis, and hepatitis B virus in a cohort of men who have sex with men in Beijing. AIDS Patient Care STDS (2010) 1.34
Medical virology of hepatitis B: how it began and where we are now. Virol J (2013) 1.34
Sexually transmitted diseases in homosexual men. Am J Public Health (1981) 1.30
Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination. Am J Public Health (1985) 1.25
Priorities for immunisation against hepatitis B. Br Med J (Clin Res Ed) (1982) 1.24
Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc Natl Acad Sci U S A (1985) 1.22
Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol (2011) 1.20
Secretion of the hepatitis B virus surface antigen from mouse cells using an extra-chromosomal eucaryotic vector. EMBO J (1983) 1.19
Strategies for hepatitis B immunisation. Gut (1992) 1.18
The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med (1991) 1.14
Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr (2013) 1.12
Nonoverlapping antigenic sites of woodchuck hepatitis virus surface antigen and their cross-reactivity with ground squirrel hepatitis virus and hepatitis B virus surface antigens. J Virol (1983) 1.12
Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest (1987) 1.09
Awareness and use of hepatitis B vaccine among homosexual male clients of a Boston community health center. Public Health Rep (1990) 1.07
Drug abuse: a new problem. Br Med J (Clin Res Ed) (1987) 1.06
Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine (2009) 1.05
Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev (1992) 1.04
Hepatitis B virus: where do we stand and what is the next step for eradication? World J Gastroenterol (2014) 1.03
Hepatitis B virus markers in prostitutes in Singapore. Genitourin Med (1985) 1.03
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
Hepatitis B virus DNA in saliva, urine, and seminal fluid of carriers of hepatitis B e antigen. Br Med J (Clin Res Ed) (1985) 1.02
Comparison of the accelerated and classic vaccination schedules against Hepatitis B: three-week Hepatitis B vaccination schedule provides immediate and protective immunity. Ann Clin Microbiol Antimicrob (2003) 0.99
Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol (2014) 0.98
In vitro antigen-induced antibody responses to hepatitis B surface antigen in man. Kinetic and cellular requirements. J Clin Invest (1984) 0.98
Hepatitis in dialysis units in the United Kingdom: a Public Health Laboratory Service Survey. J Hyg (Lond) (1981) 0.97
Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis (2001) 0.97
Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol (1997) 0.96
Host heterogeneous ribonucleoprotein K (hnRNP K) as a potential target to suppress hepatitis B virus replication. PLoS Med (2005) 0.96
Immunity to hepatitis B: analysis of antibody and cellular responses in recipients of a plasma-derived vaccine using synthetic peptides mimicking S and pre-S regions. Clin Exp Immunol (1988) 0.96
Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol (1997) 0.96
Then and now: the progress in hepatitis B treatment over the past 20 years. World J Gastroenterol (2014) 0.95
Chronic liver disease: the detection and characterization of circulating immune complexes. Immunology (1983) 0.95
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis (2012) 0.95
Hepatitis among hospital employees. West J Med (1983) 0.94
Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. BMJ (1990) 0.93
Suboptimal response to hepatitis B vaccine in Nova Scotia. Can Med Assoc J (1985) 0.93
The periodic health examination: 2. 1984 update. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J (1984) 0.93
Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines (2014) 0.93
Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Am J Public Health (1990) 0.92
Characterization of the T cell recognition of hepatitis B surface antigen (HBsAg) by good and poor responders to hepatitis B vaccines. Clin Exp Immunol (2000) 0.92
Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination. Clin Exp Immunol (1988) 0.91
Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule. J Virol (1989) 0.91
Vaccination in juvenile correctional facilities: state practices, hepatitis B, and the impact on anticipated sexually transmitted infection vaccines. Public Health Rep (2007) 0.90
Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen. J Virol (1986) 0.89
Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemic. J Viral Hepat (2010) 0.89
Sexually transmitted hepatitis: a review. Genitourin Med (1992) 0.88
Hypothesis: the pathogenesis of AIDS. Activation of the T- and B-cell cascades. Yale J Biol Med (1984) 0.88
Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology (1988) 0.88
Antibody responses to recombinant and plasma derived hepatitis B vaccines. Br Med J (Clin Res Ed) (1986) 0.88
IgG1 is pathogenic in Leishmania mexicana infection. J Immunol (2010) 0.87
Hepatitis B Infection in Canada: Epidemiology and implications for control. Can Fam Physician (1992) 0.86
Translation products of pre-S(1), pre-S(2) regions and the S gene of hepatitis B virus: susceptibility of their antigenic activities to treatment with heat, urea, formalin or pepsin. Clin Exp Immunol (1986) 0.84
Acute hepatic failure in children. Yale J Biol Med (1984) 0.84
Revaccination of non- and low- responders after a standard three dose hepatitis B vaccine schedule. Hum Vaccin Immunother (2012) 0.84
Surveillance and control of infectious diseases: progress toward the 1990 objectives. Public Health Rep (1983) 0.83
Failure of preexisting antibody against hepatitis B surface antigen to prevent subsequent hepatitis B infection. J Clin Microbiol (1983) 0.83
Allelic subtypic determinants of hepatitis B surface antigen (i and t) that are distinct from d/y or w/r. J Virol (1993) 0.83
The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol (2010) 0.82
The Gordon Wilson Lecture. The ABC's of viral hepatitis. Trans Am Clin Climatol Assoc (1992) 0.82
Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease. Arch Dis Child (1989) 0.82
Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed) (2010) 0.82
Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity. Bull World Health Organ (1992) 0.81
Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. Clin Infect Dis (2014) 0.81
Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. J Epidemiol Community Health (1992) 0.81
Of woodchucks and men: the continuing story of hepatitis B and hepatocellular carcinoma. Br Med J (Clin Res Ed) (1982) 0.80
Hepatitis A seroprevalence in homosexual and heterosexual men. Genitourin Med (1994) 0.80
Anticipated changes in sexual risk behaviour following vaccination with a low-efficacy HIV vaccine: survey results from a South African township. Int J STD AIDS (2012) 0.80
Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans. PLoS Negl Trop Dis (2013) 0.80
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine. FASEB J (2012) 0.79
Comparison of the immunogenicity, efficacy and safety of 10 micrograms and 20 micrograms of a hepatitis B vaccine: a prospective randomized trial. J Hyg (Lond) (1986) 0.79
Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia. Infect Immun (1983) 0.79
Prevalence and risk factors of hepatitis B in Spanish prostitutes. Epidemiol Infect (1987) 0.79
T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. World J Gastroenterol (2008) 0.78
Hepatitis B vaccine: prospects for duration of immunity. Yale J Biol Med (1987) 0.78
Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine. EBioMedicine (2016) 0.78
Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem Pharmacol (2016) 0.78
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med (1998) 7.07
Histological Localization of Newly-formed Desoxyribonucleic Acid. Science (1948) 6.56
Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med (1996) 6.49
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med (1975) 5.49
Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A (1995) 5.15
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol (1978) 5.02
Mucopurulent cervicitis--the ignored counterpart in women of urethritis in men. N Engl J Med (1984) 4.74
Risk factors for Kaposi's sarcoma in homosexual men. Lancet (1982) 4.70
On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med (1975) 4.11
Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med (1992) 3.56
Occupational risk for hepatitis C virus infection among New York City dentists. Lancet (1992) 3.31
Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis (1996) 3.23
A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology (2003) 3.14
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med (1991) 3.02
Clinical manifestations of vaginal trichomoniasis. JAMA (1989) 2.97
Infectious Mononucleosis: An Autopsy Report. Am J Pathol (1947) 2.88
Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet (1981) 2.75
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Altered properties of deoxyribonucleic acid nucleotidyltransferase after infection of mammalian cells with herpes simplex virus. Nature (1966) 2.61
Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA (1985) 2.48
Sexual transmission of enteric protozoa and helminths in a venereal-disease-clinic population. N Engl J Med (1981) 2.47
Epidemic of amoebiasis and giardiasis in a biased population. Br J Vener Dis (1979) 2.44
Liquid nitrogen preservation of red blood cells for transfusion; a low glycerol-rapid freeze procedure. Cryobiology (1969) 2.41
Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med (1981) 2.29
Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (1983) 2.22
Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis (1978) 2.21
An approach to evolutionary relationships of mammalian DNA viruses through analysis of the pattern of nearest neighbor base sequences. Cold Spring Harb Symp Quant Biol (1966) 2.20
HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med (1995) 2.18
Smoking and periductal mastitis. BMJ (1993) 2.16
Immunologic distinction between infectious and serum hepatitis. N Engl J Med (1970) 2.16
A new DNA-exonuclease in cells infected with herpes virus: partial purification and properties of the enzyme. J Gen Virol (1968) 2.12
Association between vaginal douching and acute pelvic inflammatory disease. JAMA (1990) 2.11
Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA (1987) 2.08
HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol (1979) 2.06
Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match. Biol Blood Marrow Transplant (2013) 2.04
Cellular immune response during uncomplicated genital infection with Chlamydia trachomatis in humans. Infect Immun (1981) 2.03
Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA (1990) 2.02
Hepatitis B virus contains pre-S gene-encoded domains. Nature (1985) 2.02
A serologic study of cytomegalovirus infections associated with blood transfusions. N Engl J Med (1971) 2.02
Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study. Ann Intern Med (1984) 2.01
The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. Sex Transm Dis (1990) 2.00
High rates of enteric protozoal infections in selected homosexual men attending a venereal disease clinic. Sex Transm Dis (1979) 2.00
The West Midlands co-operative trial of adjuvant chemotherapy for operable breast cancer. Cancer Treat Rev (1979) 1.96
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med (1984) 1.93
Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. JAMA (1974) 1.92
Human T-cell lymphotropic virus type III infection in a cohort of homosexual men in New York City. JAMA (1986) 1.90
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Distribution of antibody to hepatitis a antigen in urban adult populations. N Engl J Med (1976) 1.81
Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis (1982) 1.74
Etiology of cervical inflammation. Am J Obstet Gynecol (1986) 1.72
Stored placental blood for unrelated bone marrow reconstitution. Blood (1993) 1.72
Hepatitis B "immune" globulin: effectiveness in prevention of dialysis-associated hepatitis. N Engl J Med (1975) 1.66
Wide local excision as the sole primary treatment in elderly patients with carcinoma of the breast. Br J Surg (1989) 1.66
Cytologic manifestations of cervical and vaginal infections. I. Epithelial and inflammatory cellular changes. JAMA (1985) 1.66
Recent advances in the study of the epidemiology of hepatitis B. Am J Pathol (1975) 1.64
Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol (1993) 1.63
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J Clin Microbiol (1992) 1.61
Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet (1975) 1.59
Change points in the series of T4 counts prior to AIDS. Biometrics (1995) 1.58
Sexually transmitted enteric pathogens in male homosexual population. N Y State J Med (1977) 1.56
Familial clustering of hepatitis B infection. N Engl J Med (1973) 1.56
Prevalence of antibody to the Norwalk virus in various countries. Infect Immun (1979) 1.54
Persistence of Mycoplasma hominis after therapy: importance of tetracycline resistance and of coexisting vaginal flora. Sex Transm Dis (1984) 1.53
Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis (2001) 1.50
Wheat bran and psyllium diets: effects on N-methylnitrosourea-induced mammary tumorigenesis in F344 rats. J Natl Cancer Inst (1996) 1.50
Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study. Ann Intern Med (1984) 1.50
Parity and breast cancer: evidence of a dual effect. Br Med J (1980) 1.49
Intrafamilial spread of asymptomatic hepatitis B. Am J Med Sci (1977) 1.48
Hepatitis B antigen and antibody in blood donors: an epidemiologic study. J Infect Dis (1973) 1.46
Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med (1982) 1.46